4889 Stock Overview
Engages in the development and commercialization of pharmaceuticals and medical devices in Japan. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Renascience Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥293.00 |
| 52 Week High | JP¥442.00 |
| 52 Week Low | JP¥263.00 |
| Beta | 0.82 |
| 1 Month Change | -0.68% |
| 3 Month Change | -16.05% |
| 1 Year Change | -32.49% |
| 3 Year Change | -57.10% |
| 5 Year Change | n/a |
| Change since IPO | -64.53% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4889 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | 6.2% | 2.8% | 3.6% |
| 1Y | -32.5% | 12.8% | 16.3% |
Return vs Industry: 4889 underperformed the JP Pharmaceuticals industry which returned 12.8% over the past year.
Return vs Market: 4889 underperformed the JP Market which returned 16.3% over the past year.
Price Volatility
| 4889 volatility | |
|---|---|
| 4889 Average Weekly Movement | 5.0% |
| Pharmaceuticals Industry Average Movement | 3.8% |
| Market Average Movement | 3.6% |
| 10% most volatile stocks in JP Market | 7.2% |
| 10% least volatile stocks in JP Market | 1.9% |
Stable Share Price: 4889 has not had significant price volatility in the past 3 months compared to the JP market.
Volatility Over Time: 4889's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 4 | Keisuke Furuta | www.renascience.co.jp |
Renascience Inc. engages in the development and commercialization of pharmaceuticals and medical devices in Japan. The company is developing RS5614, a PAI-1 inhibitor product candidate for use in the treatment of chronic myeloid leukemia, malignant melanoma, non-small cell lung cancer, novel coronavirus infections, and FGF23-related hypophosphatemic rickets that is in Phase 3 clinical trials; RS5441, a PAI-1 inhibitor for use in dermatological diseases that is in Phase I clinical trials; and RS8001, a water-soluble vitamin for use in the treatment of premenstrual syndrome/premenstrual dysphoric mood disorder, autism spectrum disorder, and menopausal disorder, which is in Phase 2 clinical trials. It is also developing RS9001, a disposable ultrafine endoscope; artificial intelligence based medical solutions; and diagnostic solutions.
Renascience Inc. Fundamentals Summary
| 4889 fundamental statistics | |
|---|---|
| Market cap | JP¥3.72b |
| Earnings (TTM) | -JP¥235.00m |
| Revenue (TTM) | JP¥129.00m |
28.9x
P/S Ratio-15.8x
P/E RatioIs 4889 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4889 income statement (TTM) | |
|---|---|
| Revenue | JP¥129.00m |
| Cost of Revenue | JP¥3.00m |
| Gross Profit | JP¥126.00m |
| Other Expenses | JP¥361.00m |
| Earnings | -JP¥235.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 13, 2025
| Earnings per share (EPS) | -18.49 |
| Gross Margin | 97.67% |
| Net Profit Margin | -182.17% |
| Debt/Equity Ratio | 23.8% |
How did 4889 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/28 02:09 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Renascience Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Masao Yoshida | Ichiyoshi Research Institute Inc. |